0.4598
-0.0392
(-7.86%)
At close: January 31 at 4:00:01 PM EST
0.4568
-0.00
(-0.65%)
After hours: 7:41:29 PM EST
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 0 | 0 |
| Sales | -- | 0 |
| Net Shares Purchased (Sold) | 0 | 0 |
| Total Insider Shares Held | 11.44M | -- |
| % Net Shares Purchased (Sold) | -- | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| ZWEIFACH SANFORD S Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Mar 7, 2023 |
| MORRISON BRIGGS W. M.D. Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Mar 7, 2023 |
| UGWUMBA CHIDOZIE Director | Stock Award(Grant) at price 0.00 per share. | Indirect | 0 | Mar 7, 2023 |
| HODITS REGINA Director | Stock Award(Grant) at price 0.00 per share. | Indirect | 0 | Mar 7, 2023 |
| KLICHINSKY MICHAEL Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Mar 7, 2023 |
| TOROK MICHAEL PATRICK Director | Stock Award(Grant) at price 0.00 per share. | Indirect | 0 | Mar 7, 2023 |
| SULLIVAN MARK R General Counsel | Sale at price 0.59 per share. | Direct | 128,681 | Mar 2, 2023 |
| CANNELL THOMAS R Chief Executive Officer | Sale at price 0.59 per share. | Direct | 286,155 | Mar 2, 2023 |
| FORBES MONICA Chief Financial Officer | Sale at price 0.59 per share. | Direct | 203,013 | Mar 2, 2023 |
| MACDONALD GLEN C. Chief Technology Officer | Sale at price 0.59 per share. | Direct | 100,008 | Mar 2, 2023 |
| RYU ELLY Officer | Sale at price 0.59 per share. | Direct | 10,149 | Mar 2, 2023 |
| SULLIVAN MARK R General Counsel | Conversion of Exercise of derivative security at price 0.59 per share. | Direct | 175,029 | Mar 2, 2023 |
| CANNELL THOMAS R Chief Executive Officer | Conversion of Exercise of derivative security at price 0.59 per share. | Direct | 356,192 | Mar 2, 2023 |
| FORBES MONICA Chief Financial Officer | Conversion of Exercise of derivative security at price 0.59 per share. | Direct | 217,850 | Mar 2, 2023 |
| MACDONALD GLEN C. Chief Technology Officer | Conversion of Exercise of derivative security at price 0.59 per share. | Direct | 168,053 | Mar 2, 2023 |
| SULLIVAN MARK R General Counsel | Sale at price 0.59 per share. | Direct | 23,393 | Feb 21, 2023 |
| CANNELL THOMAS R Chief Executive Officer | Sale at price 0.59 per share. | Direct | 31,554 | Feb 21, 2023 |
| FORBES MONICA Chief Financial Officer | Sale at price 0.59 per share. | Direct | 36,332 | Feb 21, 2023 |
| MACDONALD GLEN C. Chief Technology Officer | Sale at price 0.59 per share. | Direct | 15,227 | Feb 21, 2023 |
| RYU ELLY Officer | Sale at price 0.59 per share. | Direct | 4,204 | Feb 21, 2023 |
Related Tickers
PCSA Processa Pharmaceuticals, Inc.
0.6500
-0.75%
PTIX Protagenic Therapeutics, Inc.
0.3690
-5.63%
SXTP 60 Degrees Pharmaceuticals, Inc.
0.7263
-9.21%
ENVB Enveric Biosciences, Inc.
2.0900
-46.41%
OCEA Ocean Biomedical, Inc.
0.1961
+3.48%
ONCO Onconetix, Inc.
0.5442
-3.66%
TVGN Tevogen Bio Holdings Inc.
1.4900
+11.19%
XFOR X4 Pharmaceuticals, Inc.
0.7001
+5.74%
KZIA Kazia Therapeutics Limited
1.5800
-16.84%
ATHE Alterity Therapeutics Limited
4.8000
+5.03%